X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on the advancement of its clinical development program, ELI-002, a therapeutic cancer vaccine designed with Elicio’s proprietary lymph node-targeting AMP technology, being evaluated in patients with mKRAS-driven solid tumors.
Lead Product(s): ELI-002
Therapeutic Area: Oncology Product Name: ELI-002 7P
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Elicio Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 01, 2023
Details:
The combined company will focus on advancing Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
Lead Product(s): ELI-002
Therapeutic Area: Oncology Product Name: ELI-002
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Elicio Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 17, 2023
Details:
ANG-3070, an oral tyrosine kinase inhibitor (TKI), in patients with primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN).
Lead Product(s): ANG-3070
Therapeutic Area: Nephrology Product Name: ANG-3070
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
ANG-3070 is an oral tyrosine kinase inhibitor targeting platelet-derived growth factor receptor alpha and beta and Discoidin Domain Receptors 1 and 2 (DDR1 and DDR2), tyrosine kinase receptors linked to the development of fibrosis in the kidneys and lungs.
Lead Product(s): ANG-3070
Therapeutic Area: Nephrology Product Name: ANG-3070
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
The results from the Phase 2 GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury.
Lead Product(s): Terevalefim
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ANG-3777
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC).
Lead Product(s): Terevalefim
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ANG-3777
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
The presentation describes preclinical data from a study of ANG-3070 in a mouse unilateral ureteral obstruction (UUO) model, a well-established model for obstructive renal disease.
Lead Product(s): ANG-3070
Therapeutic Area: Nephrology Product Name: ANG-3070
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2021
Details:
The overall safety profile of ANG-3777 in this trial was consistent with the overall experience in its clinical development program and consistent with the published literature in this patient population.
Lead Product(s): Terevalefim
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ANG-3777
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Details:
The Phase 1 study was a randomized, double-blind, and placebo-controlled study in healthy volunteers conducted in Australia to assess the safety, tolerability, pharmacokinetics, and food effect of ANG-3070 dosed orally.
Lead Product(s): ANG-3070
Therapeutic Area: Nephrology Product Name: ANG-3070
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2021
Details:
Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong and Macau, for all ANG-3777 nephrology indications.
Lead Product(s): Terevalefim
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ANG-3777
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: $30.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement November 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
